Literature DB >> 10981024

New developments and concepts in antimicrobial therapy for intra-abdominal infections.

Z Younes1, D A Johnson.   

Abstract

Antimicrobial therapy plays an integral role in the management of intra-abdominal infections. Recent developments include increased prevalence of antimicrobial resistance (eg, Streptococcus pneumoniae and Enterococcus species) coupled with general decline in the antimicrobial susceptibility of anaerobes and gram-negative organisms, new antibiotics and dosing regimens, and better understanding of the role of various microbial pathogens and of prophylactic antimicrobial agents. Therapeutic approaches to intra-abdominal infections, such as the various forms of peritonitis, cholecystitis, cholangitis, and diverticulitis, are reviewed here. Specific recommendations for antimicrobial therapy in various clinical settings are provided, with special emphasis on recent trends and developments that reflect changes in understanding or therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10981024     DOI: 10.1007/s11894-000-0019-7

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  48 in total

1.  Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections.

Authors:  S E Wilson
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

2.  The postantibiotic effect.

Authors:  W A Craig; B Vogelman
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

3.  Management of uncomplicated acute diverticulitis: results of a survey.

Authors:  S Schechter; J Mulvey; T E Eisenstat
Journal:  Dis Colon Rectum       Date:  1999-04       Impact factor: 4.585

4.  A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.

Authors:  P S Barie; S B Vogel; E P Dellinger; O D Rotstein; J S Solomkin; J Y Yang; T F Baumgartner
Journal:  Arch Surg       Date:  1997-12

5.  Antimicrobial therapy of experimental intraabdominal sepsis.

Authors:  W M Weinstein; A B Onderdonk; J G Bartlett; T J Louie; S L Gorbach
Journal:  J Infect Dis       Date:  1975-09       Impact factor: 5.226

6.  Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.

Authors:  C Jaccard; N Troillet; S Harbarth; G Zanetti; D Aymon; R Schneider; R Chiolero; B Ricou; J Romand; O Huber; P Ambrosetti; G Praz; D Lew; J Bille; M P Glauser; A Cometta
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis.

Authors:  C Dupeyron; N Mangeney; L Sedrati; B Campillo; P Fouet; G Leluan
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Perforated and gangrenous appendicitis: an analysis of antibiotic failures.

Authors:  P N Heseltine; A E Yellin; M D Appleman; M A Gill; F C Chenella; J W Kern; T V Berne
Journal:  J Infect Dis       Date:  1983-08       Impact factor: 5.226

9.  Enterococci highly resistant to penicillin and ampicillin: an emerging clinical problem?

Authors:  F L Sapico; H N Canawati; V J Ginunas; D S Gilmore; J Z Montgomerie; W J Tuddenham; R R Facklam
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

10.  The pharmacokinetics of the biliary excretion of ciprofloxacin.

Authors:  C S Ball; J M Manson; F Reid; D E Tweedle
Journal:  HPB Surg       Date:  1989-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.